## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE re application of: Examiner: Bunner, Bridget E. Art Unit: 1647 Kevin P. BAKER, et al. Confirmation No: 9887 Application Serial No. 10/015,394 Attorney's Docket No. 39780-2830 P1C41 Filed: December 11, 2001 For: **SECRETED AND** Customer No. 35489 TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME EXPRESS MAIL LABEL NO. EL 977 612 865 US **DATE MAILED: JANUARY 10, 2005 INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97** MAIL STOP AMENDMENT Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450 Sir: Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98. Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form Supplemental PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609. This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56. This statement qualifies under 37 C.F.R. $\S1.97$ , subsection (b) because (check all that apply): It is being filed within 3 months of the application filing date and is other than a (1) continued prosecution application under § 1.53(d) -- OR --It is being filed within 3 months of entry of a national stage (2) -- OR --It is being filed before the mail date of the first Office Action on the merits (3) 00000026 10015394 01/14/2005 HMARZI1 -- OR --

01/44/2005 HMARZII- 00000083 081641

180.00 DA

450.00 DA

01 FC:1806

02<del>-FC:125</del>2

P							
	•	[] (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.					
	37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.11 or a notice of allowance under §1.311, then:						
	•	a certification as specified in §1.97(e) is provided below; or					
		a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.					
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier office action under §1.113 or a notice of allowance under §1.311, but before payment fee, then:						
•		A. a certification as specified in §1.97(e) is completed below; and					
•		B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and					
		C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.					
	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Attorney's Docket No. 39780-2830 P1C41).  Respectfully submitted,						
	Dated:	January 10, 2005  By:  Anna L. Barry (Reg. No. 51,436)					

HELLER EHRMAN WHITE & McAULIFFE LLP

275 Middlefield Road Menlo Park, CA 94025-3506 Telephone: (650) 324-7000

Telephone: (650) 324-7000 Facsimile: (650) 324-0638

SV 2092069 v1 (39780.3330)

PE.	19						PTO/SB/0 She	08 (2/92) et 1 of 1		
Form PTO-1449  MINFORMATION DISCLOSURE STATEMENT			)-1449	Attorney's Docket No. 39780-2830 P1C41	, , ,	Application Serial No. 10/015,394				
			SURE STATEMENT	Applicant(s)  Kevin P. BAKER, et al.						
(use several sheets if necessary)				Filing Date: December 11, 2001	Gro	Group Art Unit: 1647				
<b>*</b> * * * * * * * * * * * * * * * * * *				U.S. PATENT DOCUMENTS						
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropri			
		<u> </u>	F(	DREIGN PATENT DOCUMENTS			<u> </u>			
Examiner	Ref.	Date	Document No.	Name	Class	Subclass	Transla	tion		
Initials	No.						YES	NO		
7. 7.				OTHER DOCUMENTS	s atc.)					
Examiner Initials	Ref.	(including author, title, date, pertinent pages, etc.)  Title								
	1.	Goldwaser, Itzhak, et al., "L-Glutamic Acid γ-Monohydroxamate", The Journal of Biomedical Chemistry, Vol. 274, No. 37, pp 26617-26624, September 10, 1999.								
	2.	Mueller, Wendy M., et al., "Evidence That Glucose Metabolism Regulates Leptin Secretion from Cultured Rat Adipocytes", Endocrinology, Vol. 139, No. 2, pp 551-558, December 21, 2004.								
	3.	Mueller, Wendy M., et al., "Effects of Metformin and Vanadium on Leptin Secretion from Cultured Rat Adipocytes", Obesity Research, Vol. 8, No. 7, pp 530-539, October 2000.								
	4.	Sandouk, Tagrid, et al., "The Antidiabetic Agent Pioglitazone Increases Expression of Glucose Transporters in 3T3- F442A Cells by Increasing Messenger Ribonucleic Acid Transcript Stability", Endocrinology, Vol. 133, No. 1, pp 352- 359, October 2000.								
	5.	Tafuri, Sherrie R., "Troglitazone Enhances Differentiation, Basal Glucose Uptake, and Glut 1 Protein Levels in 3T3-L1 Adipocytes", Endocrinology, Vol. 137, No. 11, pp 4706-4712, December 21, 2004.								
· · · · · ·										
			·							
	<u> </u>						<del></del>			
<del></del>						•	•			
	· · · · · ·					·	<del>.</del>	<del> </del>		
					<del></del>		·			
		-			· · · · · · · · · · · · · · · · · · ·		, <u>, , , , , , , , , , , , , , , , , , </u>			
		1								
		<del> </del>								
			· · · · · · · · · · · · · · · · · · ·							

<b>EXAMINER:</b>	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant.

\*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2092069 v1